Join the 'Myelodysplastic Syndrome' group to help and get support from people like you. How it works
Bone Marrow Cancer Patients May Benefit From Drug Combo
Posted 29 Mar 2010 by Drugs.com
MONDAY, March 29 – The drugs azacitidine and lenalidomide provide a highly effective combination treatment for bone marrow cancer, according to the results of a new study. The phase 1 study, which was funded by the U.S. National Institutes of Health, included 18 higher-risk patients, median age 68, with myelodysplastic syndromes (MDS). In people with this cancer (which is similar to leukemia), stem cells fail to mature into healthy red blood cells, white blood cells or platelets. This leads to infection, anemia and bleeding complications. The patient response rate to the combined drug treatment was 67 percent, and the treatment was well-tolerated. The combined treatment had a better response rate and remission rate than either drug used alone. This is the first time that two U.S. Food and Drug Administration-approved drugs have been combined for the treatment of MDS. The findings were ... Read more
Related support groups: Myelodysplastic Syndrome, Revlimid, Vidaza, Azacitidine, Lenalidomide
FDA Approves Five-Day Dosing Regimen for Dacogen (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
Posted 15 Mar 2010 by Drugs.com
WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ – Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells. The new outpatient dosing option provides physicians and patients with the flexibility of a dosing regimen with a reduced infusion time. Dacogen is the only hypomethylating agent approved for a five-day dosing regimen. The new regimen will be administered at a dose of 20 mg/m2 continuous intravenous (IV) infusion over one hour repeated daily for five days per cycle. The cycle is repeated every four weeks. The previously approved Dacogen three-day regimen is administered in an in-patient setting at a dose of 15 mg/m2 continuous IV ... Read more
Related support groups: Myelodysplastic Syndrome, Dacogen, Myelodysplastic Diseases
Ask a Question
You may also be interested in...
Related Condition Support Groups
Related Drug Support Groups
Neupogen, Dacogen, Vidaza, azacitidine, decitabine, filgrastim